All In MedTech

Device Trial Radar · NCT05612139

Post-market Observational Study on JTIN Telescopic Nail in Osteogenesis Imperfecta Pediatric Patients

A Single Center Post-market Clinical Follow-up (PMCF) Observational Study Evaluating the Clinical Performance and the Safety Profile of the JuniOrtho™ Telescopic Intramedullary Nail (JTIN) for the Treatment of Pediatric Patients Suffering From Osteogenesis Imperfecta

Last checked: Nov 20, 2026Latest source record: Jan 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

14

Actual

Start

Aug 27, 2024

Primary completion

Feb 20, 2025

Study completion Feb 20, 2025

Sponsor

Lead sponsor
Orthofix s.r.l.Public (OFIX)
Sponsor type
Industry
First posted
Nov 10, 2022

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 months, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study has been planned as part of the Orthofix Srl post-market active surveillance plan for the collection of data on both the clinical performance and the safety profile of the JTIN. The rationale of the proposed study is to update and support the pre-market clinical evaluation of the JTIN with Real World Evidence clinical data in a real-life surgical setting, in order to confirm the benefit/risk ratio of this medical device and to keep the CE mark under Medical Device Regulation (MDR) requirements. One selected site, experienced in the treatment of pediatric patients with OI, where the usage of JTIN is already part of the normal clinical practice, will participate in this study.

Conditions

  • Osteogenesis Imperfecta

Interventions

  • JTIN implantation surgeryDevice

    The JTIN is a self-extending intramedullary nail (telescopic rod) designed to provide fixation of femoral and/or tibial fractures, osteotomies, malunions and non-unions. The design of the JTIN includes a female and a male component, which are anchored to the proximal cortex and distal epiphysis through screw-type fixation. These two components slide from each other, allowing for extension of the JTIN as the bone structures remodel and patient growth occurs.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Procedures With at Least One Serious/Not Serious Adverse Event Certainly or Possibly Related to JTINTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Necker-Enfants Malades Hospital

    Paris, Île-de-France Region, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.